Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Homologous recombination (HR) is a critical DNA repair pathway targeted by PARP inhibitors.
• Immune checkpoint molecules, like PD-L1, are targets of cancer immunotherapies, but their non-immunological roles are less understood.

Purpose of the Study:

• To investigate the role of PD-L1 in regulating homologous recombination and DNA repair in cancer cells.
• To explore the therapeutic implications of targeting PD-L1 in conjunction with PARP inhibitors.

Main Methods:

• Genetic depletion of tumor PD-L1 in cancer cell lines and in vivo models.
• Assays for homologous recombination, nonhomologous end joining, and PARP inhibitor sensitivity (olaparib, talazoparib).
• Co-immunoprecipitation to assess protein interactions between PD-L1, BRCA1, and BARD1.

Main Results:

• Genetic depletion of tumor PD-L1 reduced homologous recombination and increased nonhomologous end joining.
• PD-L1 deficiency in tumors induced synthetic lethality with PARP inhibitors in some BRCA1 wild-type cells.
• In vivo, tumor PD-L1 depletion sensitized olaparib-resistant tumors to olaparib.
• PD-L1 interacted with BARD1, promoting BRCA1 nuclear accumulation independently of BRCA1/BARD1 expression levels.

Conclusions:

• Tumor PD-L1 has an immune-independent function in regulating BRCA1-mediated DNA repair.
• Targeting tumor PD-L1 represents a potential therapeutic strategy to overcome PARP inhibitor resistance.
• PD-L1's role in DNA repair offers a potential biomarker for predicting treatment response.